Characterization of Wound Microbes in Epidermolysis Bullosa: Results from the Epidermolysis Bullosa Clinical Characterization and Outcomes Database
Overview
Pediatrics
Authors
Affiliations
Background/objectives: Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected with bacteria. A subset of EB patients are at risk for squamous cell carcinoma, and bacterial-host interactions have been considered in this risk. The EB Clinical Characterization and Outcomes Database serves as a repository of information from EB patients at multiple centers in the United States and Canada. Access to this resource enabled broad-scale analysis of wound cultures.
Methods: A retrospective analysis of 739 wound cultures from 158 patients from 13 centers between 2001 and 2018.
Results: Of 152 patients with a positive culture, Staphylococcus aureus (SA) was recovered from 131 patients (86%), Pseudomonas aeruginosa (PA) from 56 (37%), and Streptococcus pyogenes (GAS) from 34 (22%). Sixty-eight percent of patients had cultures positive for methicillin-sensitive SA, and 47%, methicillin-resistant SA (18 patients had cultures that grew both methicillin-susceptible and methicillin-resistant SA at different points in time). Of 15 patients with SA-positive cultures with recorded mupirocin susceptibility testing, 11 had mupirocin-susceptible SA and 6 patients mupirocin-resistant SA (2 patients grew both mupirocin-susceptible and mupirocin-resistant SA). SCC was reported in 23 patients in the entire database, of whom 10 had documented wound cultures positive for SA, PA, and Proteus species in 90%, 50%, and 20% of cases, respectively.
Conclusions: SA and PA were the most commonly isolated bacteria from wounds. Methicillin resistance and mupirocin resistance were reported in 47% and 40% of patients tested, respectively, highlighting the importance of ongoing antimicrobial strategies to limit antibiotic resistance.
Quintana-Castanedo L, Sanchez-Ramon S, Maseda R, Illera N, Perez-Conde I, Molero-Luis M Exp Dermatol. 2024; 33(8):e15146.
PMID: 39075828 PMC: 11605501. DOI: 10.1111/exd.15146.
Syafarina I, Mazaya M, Indrawati A, Akbar S, Sukowati C, Sadikin R Curr Drug Targets. 2024; 25(6):404-415.
PMID: 38566380 DOI: 10.2174/0113894501290512240327091531.
Epidermolysis bullosa in a mother-infant dyad.
Prashanth R, Kamble P, Kumari A, Haribalakrishna A, Mahajan S Oxf Med Case Reports. 2023; 2023(11):omad124.
PMID: 38033404 PMC: 10686001. DOI: 10.1093/omcr/omad124.
Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa.
Scollan M, Levin L, Lucky A, Hook K, Peoples K, Bruckner A Pediatr Dermatol. 2023; 40(5):863-865.
PMID: 37364926 PMC: 10543531. DOI: 10.1111/pde.15383.
De Rose D, Pugnaloni F, Martini L, Bersani I, Ronchetti M, Diociaiuti A Antibiotics (Basel). 2023; 12(4).
PMID: 37106994 PMC: 10135205. DOI: 10.3390/antibiotics12040632.